Benefit from Renal Cancer Drug Appears Small MedPage Today ... for advanced renal cell carcinoma -- vascular endothelial growth factor (VEGF) receptor inhibitors sorafenib, sunitinib and pazopanib, and VEGF antibody bevacizumab; and mammalian target of rapamycin (mTOR) inhibitors temsirolimus and everolimus. ... |
